Novo Nordisk - HealthQuill

June 27, 2024: Novo Nordisk’s end-stage trial for hypertension drug has failed to meet its primary goal and the Danish multinational has recognised an impairment loss of 5.7 Danish crowns or $817 million in the second quarter of this year.

Novo’s end-stage hypertension trial drug fails, $817m impairment loss

Novo Nordisk’s end-stage trial for hypertension drug has failed to meet its primary goal and the Danish multinational has recognised an impairment loss.

by HealthQuill
June 27, 2024
0 Comments

Israel’s Teva Pharmaceuticals will start selling a generic version of Novo Nordisk’s type 2 diabetic drug Victoza in the US market.

Drugs Health Pharma

Teva to sell generic version of Novo Nordisk’s diabetic drug in US

Israel’s Teva Pharmaceuticals will start selling a generic version of Novo Nordisk’s type 2 diabetic drug Victoza in the US market.

by HealthQuill
June 25, 2024
0 Comments

Novo Nordisk, a Danish pharmaceutical multinational, will invest $4.1 billion to build a new factory in the US to make obesity and chronic disease drugs, according to a company statement.

Drugs Health Pharma

Novo Nordisk to set up $4.1 billion injectables facility in US’s North Carolina

Novo Nordisk, a Danish pharmaceutical multinational, will invest $4.1 billion to build a new factory in the US to make obesity and chronic.

by HealthQuill
June 25, 2024
0 Comments

The World Health Organization has issued a medical product alert on falsified semaglutides, an active ingredient in Ozempic, a diabetic drug made by Novo Nordisk and weight-loss medication Wegovy.

Drugs Health Pharma

WHO issues medical alert on falsified weight-loss, diabetic drugs

The World Health Organization has issued a medical product alert on falsified semaglutides, an active ingredient in Ozempic, a diabetic drug made by.

by HealthQuill
June 21, 2024
0 Comments

The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA refused approval for a once-weekly jab to control blood sugar levels in people with type 1 diabetes, with seven members voting for and four against.

Drugs Health Pharma

FDA panel rejects Novo Nordisk’s weekly jab to treat type 1 diabetes

The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA refused approval for a once-weekly jab to control blood sugar levels in people.

by HealthQuill
May 26, 2024
0 Comments

Novo Nordisk, Europe’s most valuable company, has raised its 2024 revenue outlook on the back of its popular weight-loss drug Wegovy, as it announced its January to March operating profit rose 27% to Danish kroner 31.8 billion.

Drugs Health Pharma

Novo Nordisk raises sales forecast on strong demand for anti-obesity drug

HQ Team May 2, 2024: Novo Nordisk, Europe’s most valuable company, has raised its 2024 revenue outlook on the back of its popular.

by HealthQuill
May 2, 2024
0 Comments

US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side effects.

Drugs Health Pharma

Viking Therapeutics’ weight-loss drug shows ‘positive’ results in early trials

US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side.

by HealthQuill
March 27, 2024
0 Comments

Novo Nordisk, one of the world’s most valuable companies, will acquire Germany-based Cardior Pharmaceuticals, a firm that specialises in heart diseases, for up to 1.03 billion euros ($1.1 billion).

Drugs Health Pharma

Novo to buy Cardior for $1.1b to expand cardiovascular segment

HQ Team March 25, 2024: Novo Nordisk, one of the world’s most valuable companies, will acquire Germany-based Cardior Pharmaceuticals, a firm that specialises.